Skip to main content

Table 5 Risk factors for 30-day patient mortality grouped by MRSA risk score

From: Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

 

Adjusted Odds ratio (95 % confidence interval)

Risk score

All (n = 80,330)

0–1 (n = 41,282)

2–5 (n = 37,975)

6–10 (n = 1,073)

MRSA therapy

1.22 (1.17-1.27)

1.47 (1.37-1.58)

1.05 (1.00-1.11)

0.57 (0.42-0.77)

Age (1-year increments)

1.05 (1.04-1.05)

1.05 (1.05-1.06)

1.04 (1.03-1.04)

1.05 (1.02-1.08)

Race

0.99 (0.94-1.05)

0.95 (0.86-1.06)

0.98 (0.91-1.05)

1.18 (0.85-1.64)

Hispanic ethnicity

0.85 (0.79-0.92)

0.84 (0.73-0.96)

0.86 (0.79-0.95)

0.79 (0.47-1.32)

Comorbid conditions

 Myocardial infarction

1.14 (1.06-1.23)

1.11 (0.94-1.30)

1.05 (0.97-1.14)

1.06 (0.74-1.51)

 Heart failure

1.16 (1.11-1.21)

1.07 (0.97-1.17)

1.11 (1.05-1.18)

1.16 (0.88-1.53)

 COPD

0.96 (0.91-1.00)

0.92 (0.85-1.00)

0.95 (0.89-1.01)

1.30 (0.96-1.77)

 Liver disease

1.79 (1.54-2.08)

1.34 (0.97-1.87)

1.80 (1.50-2.14)

3.46 (1.08-13.51)

 Renal disease

0.98 (0.93-1.04)

0.91 (0.81-1.02)

0.96 (0.90-1.03)

1.12 (0.83-1.53)

 Neoplastic disease

1.54 (1.47-1.60)

1.57 (1.46-1.69)

1.48 (1.40-1.56)

1.18 (0.87-1.59)

Medication use, by class

 Cardiovascular medications

0.72 (0.69-0.75)

0.60 (0.56-0.64)

0.78 (0.73-0.82)

0.91 (0.66-1.24)

 Anti-diabetic medications

0.92 (0.87-0.96)

0.78 (0.71-0.86)

0.95 (0.90-1.01)

0.95 (0.70-1.29)

 Inhaled corticosteroids

0.76 (0.72-0.81)

0.73 (0.65-0.81)

0.80 (0.74-0.86)

1.13 (0.77-1.65)

 Pulmonary medications

1.00 (0.94-1.05)

0.93 (0.85-1.03)

1.03 (0.97-1.11)

0.68 (0.48-0.97)

Vasopressors

1.81 (1.70-1.93)

3.00 (2.49-3.61)

1.66 (1.55-1.79)

1.52 (1.12-2.04)

Mechanical ventilation

 Invasive

1.08 (1.01-1.16)

2.48 (1.98-3.10)

1.02 (0.95-1.10)

0.92 (0.65-1.29)

 Noninvasive

1.16 (1.06-1.27)

2.03 (1.60-2.57)

1.03 (0.94-1.13)

1.22 (0.80-1.86)

Organ failure

 Respiratory

2.48 (2.34-2.63)

3.84 (3.45-4.29)

2.03 (1.90-2.18)

1.47 (1.06-2.04)

 Cardiovascular

1.91 (1.80-2.02)

1.90 (1.68-2.15)

1.81 (1.69-1.94)

1.36 (1.02-1.82)

 Neurological

1.53 (1.38-1.71)

1.64 (1.33-2.02)

1.40 (1.23-1.58)

1.92 (1.03-3.65)

 Renal

1.58 (1.51-1.66)

1.77 (1.62-1.94)

1.46 (1.38-1.55)

1.15 (0.87-1.51)

 Hematologic

1.65 (1.52-1.80)

1.97 (1.67-2.32)

1.53 (1.39-1.69)

1.18 (0.73-1.90)

 Hepatic

2.54 (2.08-3.11)

3.21 (2.05-5.00)

2.38 (1.90-2.99)

0.66 (0.20-2.16)

Antibiotic therapy

 GC-CAP therapy

0.67 (0.63-0.70)

0.60 (0.54-0.67)

0.73 (0.69-0.79)

0.73 (0.50-1.08)

 Pseudomonal therapy

1.25 (1.19-1.32)

1.68 (1.53-1.85)

1.05 (0.99-1.12)

0.76 (0.54-1.06)

 Atypical therapy

0.45 (0.43-0.48)

0.59 (0.53-0.66)

0.46 (0.43-0.49)

0.75 (0.52-1.08)

MRSA culture positivity

0.66 (0.59-0.74)

0.58 (0.45-0.73)

0.66 (0.58-0.75)

0.56 (0.31-0.99)

  1. Bold indicates statistical significance; MRSA Methicillin-resistant Staphylococcus aureus; Race was ordered as black versus nonblack; COPD Chronic obstructive pulmonary disease, GC-CAP Guideline-concordant community-acquired pneumonia
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us